Literature DB >> 10416127

Expression of surface antigens during the differentiation of human dendritic cells vs macrophages from blood monocytes in vitro.

A D Santin1, P L Hermonat, A Ravaggi, M Chiriva-Internati, M J Cannon, J C Hiserodt, S Pecorelli, G P Parham.   

Abstract

High expression of MHC antigens and adhesion/costimulation molecules is considered as one of the major characteristics qualifying macrophages (M) and dendritic cells (DC) as professional antigen presenting cells. Since accessory activity of M is known to be weaker than that of DC but both M or DC can differentiate from blood monocytes (MO) depending on culture conditions (i.e. GM-CSF vs GM-CSF/IL-4), we investigated the kinetics of expression of MHC antigens and several adhesion/costimulation molecules during the differentiation of DC or M from blood MO. Blood MO cultured with GM-CSF consistently induced M that showed adherence to plastic and CD14 expression. In contrast, MO cultured with GM-CSF/IL-4 rapidly became nonadherent, acquired DC morphology and lost CD14 expression. M but not DC proliferated as demonstrated by [H3]thymidine incorporation. MHC Class I was highly expressed in both M and DC. In contrast, MHC Class II molecules were significantly higher on DC compared to M. CD80 was upregulated on both DC and M but only on a subset of cells. CD80 expression peaked at day 3 on M and declined thereafter, while on DC expression increased significantly until day 10. CD86 was upregulated on the majority of DC and M. However, while M maintained stable expression of CD86 after day 3, DC progressively upregulated CD86 throughout the culture period. CD1a expression was initially low in both cell types and peaked at day 3 in M declining thereafter, while expression remained stable on DC until day 10. ICAM-1 expression was significantly upregulated on M when compared to DC at day 3. However, on M, ICAM-1 expression became undetectable by day 5 while on DC it increased through day 10. Similarly, CD40 was transiently expressed on M until day 5, while on DC it continuously increased until day 10. Finally, in contrast to other antigens, LFA-3 was always more strongly expressed on M than DC at all culture periods. Taken together, these data suggest that M showed a rapid but transient upregulation in the expression of adhesion/costimulation molecules, suggesting that maximal accessory ability is reached by M at an earlier time point than DC. Significant differences in surface antigen expression DC vs M were recognizable for MHC class II, CD86, CD80, CD1a, CD40 and ICAM-1. Specifically, major differences occurred for MHC class II, CD86, CD40 and ICAM-1. Therefore, the higher accessory ability of DC compared to M in naive T cell priming may be related to qualitative and quantitative differences in expression of these immunologically important surface molecules.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416127     DOI: 10.1016/s0171-2985(99)80069-2

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  11 in total

1.  Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells.

Authors:  Samantha Jilek; Michael Ulrich; Hans P Merkle; Elke Walter
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

2.  Dendritic cells and macrophages are productively infected by poliovirus.

Authors:  Rahnuma Wahid; Martin J Cannon; Marie Chow
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Virus-specific CD4+ and CD8+ cytotoxic T-cell responses and long-term T-cell memory in individuals vaccinated against polio.

Authors:  Rahnuma Wahid; Martin J Cannon; Marie Chow
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; S Pecorelli; J J Roman; G P Parham; M J Cannon
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

5.  Lipoprotein-dependent and -independent immune responses to spirochetal infection.

Authors:  Juan C Salazar; Constance D Pope; Meagan W Moore; Jonathan Pope; Thomas G Kiely; Justin D Radolf
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

6.  Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12.

Authors:  R Blackstock; N McElwee; E Neller; J Shaddix-White
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

7.  Identifying and structurally characterizing CD1b in Aotus nancymaae owl monkeys.

Authors:  Fabio Castillo; Carlos Guerrero; Esperanza Trujillo; Gabriela Delgado; Pilar Martinez; Luz M Salazar; Paola Barato; Manuel E Patarroyo; Carlos Parra-López
Journal:  Immunogenetics       Date:  2004-09-10       Impact factor: 2.846

8.  Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Authors:  Alessandro D Santin; Stefania Bellone; Michela Palmieri; Alessandro Zanolini; Antonella Ravaggi; Eric R Siegel; Juan J Roman; Sergio Pecorelli; Martin J Cannon
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

9.  Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.

Authors:  A D Santin; S Bellone; A Ravaggi; J J Roman; S Pecorelli; G P Parham; M J Cannon
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

10.  Human breast cancer cells educate macrophages toward the M2 activation status.

Authors:  Sofia Sousa; Régis Brion; Minnamaija Lintunen; Pauliina Kronqvist; Jouko Sandholm; Jukka Mönkkönen; Pirkko-Liisa Kellokumpu-Lehtinen; Susanna Lauttia; Olli Tynninen; Heikki Joensuu; Dominique Heymann; Jorma A Määttä
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.